DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT03287076

TEXAIS

UnknownPhase 2

Trial of EXenatide in Acute Ischaemic Stroke

A Multicentre, Randomised Controlled Trial of Exenatide Versus Standard Care in Acute Ischemic Stroke (TEXAIS)

Asset

Exenatide

Subcutaneous · GLP-1 agonist

Listed sites

15

Recruiting sites

—

Enrollment

350

actual

Study population

Stroke

Key I/E criterion

—

Primary endpoint

•Improved neurological outcome

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT03287076
Org study IDNTA1127
Secondary ID2018-004325-88

Timeline

Milestones

Study first posted2017-09-19actual
Study start2017-11-23actual
Last update posted2021-09-14actual
Primary completion2021-10-04estimated
Study completion2021-12-31estimated

Assets

Investigational agents

Exenatide

Study populations

Who this study enrolls

Stroke

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Males and females 18 years or older
•Acute Ischaemic Stroke - CT brain exclusion of haemorrhagic stroke
•Blood glucose level on admission ≥ 4mmol/L
•First trial treatment possible within 9 hours of stroke onset
•Pre-morbid /mRS score of 0-2

Exclusion criteria

•Haemorrhagic stroke
•Poor clinical prognosis /palliation (considered unlikely to survive beyond 14 days post stroke).
•Any known allergy or hypersensitivity to Exenatide
•Females who are pregnant (known or suspected) or currently breastfeeding
•Any past history of pancreatitis or evidence of active pancreatitis
•History of active severe gastrointestinal disease (including but not limited to gastroparesis and dumping syndrome)
•Current chronic kidney disease stage 4 or 5 (creatinine clearance <30ml/min)
•Current participation in another interventional clinical trial
•Inability to provide consent (participant or person responsible as local laws apply)
•Current use of Exenatide (Byetta®), or other GLP-1 agonist diabetes medication
•Patients considered unlikely to be able to be followed up at 3 months (including but not limited to geographical location of patient at 3 months)

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other clinical outcomes
3
Glycemic / diabetes
1

Glycemic / diabetes

1 endpoint
Secondary/protocol endpoint

post stroke hyperglycaemia

Time frame:90 days

threshold achievement, improvement

Other clinical outcomes

3 endpoints
Primary/protocol endpoint

improved neurological outcome

Time frame:7 days

threshold achievement, improvement

Secondary/protocol endpoint

Modified Rankin Scale

Time frame:90 days

descriptive, improvement

Secondary/protocol endpoint

NIHSS

Time frame:90 days

change from baseline, improvement

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.